DRESDEN, Germany, Mar. 22, 2021 (BioInformant) — denovoMATRIX GmbH, a developer of technologies which enable high quality stem cell expansion, announced the launch of a new range of products for the expansion, banking and maintenance of induced pluripotent stem cells (iPSC). The product line, termed myMATRIX iPSC, are chemically defined, ready-to-use consumables, designed to simplify and accelerate iPSC culture. [Read more…]
Notch Therapeutics Closes $85M Series A Financing to Develop Pipeline of Renewable Stem Cell-Derived Cancer Immunotherapies
— Financing supports advancement of initial T cell-based pipeline for cancer and
expanded development of Engineered Thymic Niche (ETN) platform for multiple immune cell types—
VANCOUVER, British Columbia, February 10, 2021— Notch Therapeutics, Inc., a biotechnology company developing renewable, induced pluripotent stem cell (iPSC)-derived cell therapies for cancer, announced today the closing of an oversubscribed U.S. $85 million Series A financing. [Read more…]
LifePlus Stem Cells Delivers its First Allogeneic Mesenchymal Stem Cells for the Treatment of Arthritis
LifePlus Stem Cells, a provider of innovative stem cell advancements, specialising in regenerative rehabilitation announces their first injection of its umbilical cord-derived allogeneic mesenchymal stem cells. Using a unique and highly regulated manufacturing process, LifePlus Stem Cells is able to provide patients and clinicians with the world’s purest allogeneic mesenchymal stem cells – achieving purity levels of well over 80%.
The Complete Guide To Virtual Stem Cell Conferences in 2021
As the world has been rocked by the COVID-19 pandemic, most in-person conferences have been canceled or switched to online formats. This goes for stem cell conferences too. However, stem cell conferences are still happening in 2021, albeit mostly virtual.
Here is your complete guide to virtual stem cell conferences in 2021. Learn more below to decide which ones to attend. For ease of reference, they are organized by date. [Read more…]
Implant Therapeutics To Engineer iPSC-MSC Cells Containing panCELLa’s Technologies
TORONTO, Jan. 8, 2021– panCELLa’s intent to develop therapeutic products in the mesenchymal stem cell (MSC) and pancreatic islet space has recently led to the creation of Implant Therapeutics.
Implant Therapeutics, under the guidance of Dr. Mahendra Rao, is engineering iPSC-MSC cells containing panCELLa’s FailSafe™ and induced Allogeneic Cell Tolerance (iACT Stealth Cell™) technologies. These iPSC MSC cells are hypo-immunogenic and are an ideal choice for bone, cartilage and tendon replacement strategies combining the advantages of allogeneic and autologous cells as well as allowing them to be used as ex-vivo gene therapy vehicles. [Read more…]
- « Previous Page
- 1
- …
- 90
- 91
- 92
- 93
- 94
- …
- 201
- Next Page »